Document Detail


Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
MedLine Citation:
PMID:  18752933     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Anti-cyclic citrullinated peptide antibodies (anti-CCP) are reported to be found in 5-13% of patients with psoriatic arthritis (PsA). However, whether anti-CCP-positive PsA patients and rheumatoid arthritis (RA) patients have a similar pathophysiological background still remains uncertain. OBJECTIVE: To determine the prevalence of anti-CCP antibodies in patients with PsA and characterize these anti-CCP-positive patients of PsA. METHODS: We measured the serum levels of the anti-CCP antibodies in patients with PsA (n=16), psoriasis (n=15), RA (n=9) and healthy controls (n=11). Serum levels of rheumatoid factor (RF), matrix metalloproteinase-3 (MMP-3), cartilage oligomeric matrix protein (COMP), interleukin (IL)-23p19 and IL-12p40 were also measured in all the samples. RESULTS: Two of the 16 PsA patients (13%) were positive for anti-CCP antibodies with high titers of RF. However, the serum IL-23p19 levels were two orders of magnitude higher in the anti-CCP-positive PsA patients as compared with those in the RA patients and anti-CCP-negative PsA patients. No significant elevation of the serum levels of MMP-3, COMP and IL-12p40 was found in these patients. CONCLUSION: Thirteen percent of the PsA patients were positive for anti-CCP. These patients do not fulfill the American College of Rheumatology (ACR) classification criteria for RA so far. Furthermore, they showed the typical clinical features of PsA rather than those of RA. Although anti-CCP-positive PsA patients may possibly be have a risk of developing RA, we propose that these patients be classified, for the moment, into a independent subtype of PsA, as a different entity from RA.
Authors:
Sayaka Shibata; Yayoi Tada; Mayumi Komine; Naoko Hattori; Satsuki Osame; Naoko Kanda; Shinichi Watanabe; Hidehisa Saeki; Kunihiko Tamaki
Related Documents :
3442963 - Malnutrition in rheumatoid arthritis.
12695163 - Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors i...
12516813 - Are preoperative serum calcium, parathyroid hormone, and adenoma weight predictive of p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-08-26
Journal Detail:
Title:  Journal of dermatological science     Volume:  53     ISSN:  0923-1811     ISO Abbreviation:  J. Dermatol. Sci.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-22     Completed Date:  2009-03-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9011485     Medline TA:  J Dermatol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  34-9     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. sayakashibata-tky@umin.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Anti-Idiotypic / blood*
Arthritis, Psoriatic / blood*,  ethnology,  immunology
Biological Markers / blood
Case-Control Studies
Extracellular Matrix Proteins / blood
Female
Glycoproteins / blood
Humans
Interleukin-12 Subunit p40 / blood
Interleukin-23 Subunit p19 / blood*
Japan
Male
Matrix Metalloproteinase 3 / blood
Middle Aged
Peptides, Cyclic / immunology*
Rheumatoid Factor / blood
Chemical
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Biological Markers; 0/Extracellular Matrix Proteins; 0/Glycoproteins; 0/Interleukin-12 Subunit p40; 0/Interleukin-23 Subunit p19; 0/Peptides, Cyclic; 0/cartilage matrix protein; 0/cyclic citrullinated peptide; 9009-79-4/Rheumatoid Factor; EC 3.4.24.17/Matrix Metalloproteinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin.
Next Document:  Light-weight plastination.